Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04171128

Enrollment

119

Registered

2019-11-20

Start date

2019-02-02

Completion date

2020-08-01

Last updated

2021-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

procalcitonin

Brief summary

The investigators intend to observe the inflammatory marker procalcitonin (PCT) in comparison with patient variables on morbidity, mortality and antibiotic treatment. The overall aim is to observe if a low PCT value can have potential in reducing unessesary antibiotic use in seasonal influenza patients.

Detailed description

This is an observational study of the clinical utility of early PCT measurements in seasonal influenza, with particular attention to PCT's predictive value for prognosis and bacterial respiratory superinfection. The aim is to evaluate PCT as a supplementary aid in the standard clinical evaluation of influenza patients. Patients may be included if a positive influenza test is reported within 48 hours after an initial clinical suspicion of influenza, and the hospital stay is lasting more than one day. The investigators have included 74 patients from the second half of the 2018-19 influenza season and will continue to include patients from the complete 2019-20 season. Primary endpoints: Mortality (in-hospital and within 30 days post-discharge), bacterial respiratory tract superinfection. Secondary endpoints: Intensive care unit stay, the proportion of patients on antibiotic use and total antibiotic use in doses and LOT (length-of-treatment).

Interventions

BEHAVIORALantibiotic stewardship efforts

The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient admitted to the hospital with positive influenza test

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
mortality	30 days	From the national registry the investigators will register wheather or not the patient has died within day 14 and day 30, and in case of dead the date will be registered

Secondary

Measure	Time frame	Description
antibiotic use	up to one year	From a elecronical medical chart (Metavision) the investigators will search and register the type of antibiotic used, the days of treatment and the total dose given in grams

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026